Date: 5.8.2014
Technology offer: Anticancer agents based on human pancreatic ribonuclease
Reference: 13 ES 252K 3SRH
Summary: A Catalan research group has developed a new anticancer therapy directed against nuclear RNA based on the engineering of human pancreatic ribonuclease. These ribonucleases are non-genotoxic drugs and it is thought very difficult that they may generate drug resistance phenotype. Their human origin warrants poor or null immunogenicity in clinical uses. License agreement or a technology development agreement with companies is sought.
For more information click here.
Technologické nabídky a poptávky zpracovává BIC Plzeň, partner sítě Enterprise Europe Network.
Gate2Biotech - Biotechnology Portal - All Czech Biotechnology information in one place.
ISSN 1802-2685
This website is maintained by: CREOS CZ
© 2006 - 2024 South Bohemian Agency for Support to Innovative Enterprising (JAIP)
Interesting biotechnology content:
Science Magazine
Biotechnology Books - Huge database of biotechnology books
Solar panels in your eyeballs: Self-powered bionics are on the way
New understanding of ancient genetic parasite may spur medical breakthroughs